Long-term survival from adenocarcinoma of the esophagus after transthoracic and transhiatal esophagectomy by Kjell K Ovrebo et al.
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
Ovrebo et al. World Journal of Surgical Oncology 2012, 10:130
http://www.wjso.com/content/10/1/130RESEARCH Open AccessLong-term survival from adenocarcinoma of the
esophagus after transthoracic and transhiatal
esophagectomy
Kjell K Ovrebo1,2*, Stein A Lie2,3, Ole D Laerum4, Knut Svanes1,2 and Asgaut Viste1,2Abstract
Background: The effects of transthoracic or transhiatal esophagectomy on the long-term survival of patients who
had adenocarcinoma of the esophagus were compared, as were factors applicable in preoperative stratification of
patient treatment.
Methods: A cohort of 147 consecutive patients with adenocarcinoma of the esophagus was evaluated for
esophagectomy between 1984 and 2000. The patients were followed prospectively and observed survival rates of
patients with a transthoracic or transhiatal approach to esophagectomy were compared by standardized mortality
ratio (SMR) and relative mortality ratio (RMR) using the expected survival of a matched Norwegian population.
Results: A R0 resection was performed by transthoracic (n= 33) or a transhiatal (n= 55) esophagectomy in 88 (60%)
patients with a median age of 61 (range: 35–77) and 70 (42–88) years, respectively (P <0.001). Tumor stages and
other possible risk factors were similar in the two groups. Transthoracic or transhiatal esophagectomy resulted in a
median survival time of 20.5 (95% confidence interval (CI): 10.4–57.6) and 16.4 (10.6–28.7) months, respectively. The
respective survival rates were 31.2% and 27.8% by 5 years, and 21.3% and 16.6% by 10 years with an overall RMR of
1.14 (P = 0.63). Median survival time in the absence or presence of lymph node metastases was 74.0 (95% CI:
17.5–166.4) and 10.7 (7.9–14.9) months. The corresponding survival rates by 10 years with non-involved or involved
nodes were 48.9% and 3.8% respectively (RMR 2.22, P = 0.007). Patients with a pT1-tumor were few and the survival
rate was not very different from that of the general population (SMR = 1.7, 95% CI: 0.7–4.1). The median survival
time of patients with a pT2-tumor was 30.4 (95% CI: 9.0–142) months and with a pT3-tumor 14 (9.2–16.4) months.
The survival rates by 10 years among patients with a pT1 tumor were 57.0% (95% CI: 14.9–78.9), pT2 33.3%
(11.8–52.2), and pT3 7.1% (1.9–15.5). The relative mortality for T3 stages compared to T1 stages was statistically
significant (RMR= 3.22, P = 0.024).
Conclusion: Transthoracic and transhiatal esophagectomy are both effective approaches for treatment of
adenocarcinoma of the esophagus and survival of more than 10 years can be expected without adjuvant
chemotherapy. However, increasing depth of tumor invasion and lymph node metastases reduce life expectancy.Background
Adenocarcinoma of the lower esophagus and the gastro-
esophageal (GE) junction represent an increasing health
problem. In 2005 there were on a worldwide basis nearly
half a million new cases and, due to an extremely bad
prognosis, almost as many deaths. Once an invasive
adenocarcinoma has developed, the diagnosis is usually* Correspondence: kkovrebo@gmail.com
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reproduction in any medium, provided the ormade at a stage where the disease is already advanced.
In Europe and the USA there has been an almost six-
fold increase in the incidence of these tumors from 1975
to 2000, and this increase seems to continue [1,2].
Although surgery dominates the treatment of local dis-
ease, comparative studies between different surgical
approaches are few and controversies still exists on the
extent of esophagus resection, lymph node dissection
and preferred fields of dissection [3]. Transthoracic eso-
phagectomy is reported with superior survival rates
compared with transhiatal esophagectomy [4-7], but theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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not identify any statistical significant difference between
the survival rates of patients subject to transthoracic
esophagectomy with extended en bloc lymph node re-
section or transhiatal esophagectomy with limited ab-
dominal lymph node dissection [9,10]. Other reports
indicate that gastrectomy with partial esophagectomy
and transhiatal esophagectomy for cardiac cancers ob-
tain similar survival rates [11-14]. Minimal invasive
approaches to esophagectomy have increased exponen-
tially in England, but mortality rates and length of stay is
similar to that of patients treated with conventional sur-
gery [15].
The precision in localization of adenocarcinoma in the
distal esophagus may vary and reports on epidemiology
and surgical treatment are therefore difficult to evaluate.
The Siewert’s classification improved the differentiation
and the precision in reports on these tumors and the
classification may serve as a base for selection among
different surgical approaches [16]. Similar support for
treatment algorithms are not necessarily found in the
seventh edition of TNM classification [17]. Most studies,
however, include patients with both Siewert type I and
type II cardiac cancers. When focusing on type I cardiac
or distal esophagus adenocarcinoma, survival rates
obtained by transthoracic esophagectomy appear superior
to that by transhiatal esophagectomy [10]. The diversity of
surgical approaches and survival benefit of patients sub-
jected to esophagectomy for adenocarcinoma of the distal
esophagus suggest that further studies are needed in order
to establish the preferred surgical approach before the
addition of different types of multimodal therapy con-
found evaluation of the surgical approaches.
This study was performed in order to compare the
long-term results of transthoracic or transhiatal esopha-
gectomy among patients with type I adenocarcinoma of
the esophagus. These patients were all operated before
the introduction of multimodal radiochemotherapy.
In order to adjust for all possible demographic confoun-
ders that could distort the results and the survival ana-
lyses, patient survival was compared with and adjusted for
population mortality rates.
Methods
In the period 1984–2000, 147 consecutive patients with
adenocarcinoma of the distal esophagus were evaluated
for surgery in this referral center for patients with car-
cinoma of the esophagus in Western Norway. Patients
were registered and followed prospectively.
Distant metastases or poor health obviated a curative re-
section in 33 (22%) of the patients. Another 26 (18%)
patients received an esophagectomy but distant metasta-
ses or involved margins of a locally advanced tumor were
identified late during the operation implying residualtumor tissue in the patient after resection (R2-resection).
This is a prospective study of the remaining 88 (60%)
patients subjected to a R0 resection for adenocarcinoma
of the esophagus. The patients were not offered adjuvant
or neoadjuvant radiochemotherapy. The median time of
postoperative observation was 16 (range 0–203) months.
Patients subject to a transthoracic or a transhiatal resec-
tion were observed for a median of 20 (range 3–203) and
16 (range 0–157) months, respectively.
Staging
All patients were evaluated by endoscopy. Tumors at or
close to the GE junction were classified as adenocarcin-
oma of the esophagus if the tumor was not visible at the
cardia with the endoscope looped or inverted in the
stomach. Siewert’s classification [16] of tumors at the
GE junction has been introduced, but patients are still
offered esophagectomy for tumors invisible at the cardia
when inspected from the stomach with a looped endo-
scope. Preoperative endoscopic ultrasonography (EUS)
was introduced for staging of all patients with carcinoma
of the esophagus in this department from 1991 [18].
Computed tomography (CT) of the chest and abdomen
as well as ultrasonography of the liver and chest radio-
graphs were used for identification of distant metastases.
Invasion of the tumor into adjacent organs (Stage III,
T4, any N, any M) or distant metastases (Stage IV B)
precluded surgery. Surgery was also prohibited among
patients with severe symptomatic heart or lung disease,
poor general health or cerebral dysfunction.
Surgical procedures
Esophagectomy was performed with a transhiatal or
a transthoracic approach. The surgical approach was
determined by patient comorbidity and the surgeons
preferred technique.
The transhiatal approach was performed according to
Orringer [5,19] with an upper abdominal midline and a
left cervical incision. A generous incision of the esopha-
geal hiatus allowed dissection in the lower mediastinum
with circumferential removal of the fat pad in the lower
mediastinum followed by blunt dissection of the oral
esophagus from the esophageal hiatus and thoracic inlet
[5,19].
The transthoracic procedure was performed with the
patient in a left lateral position, and a right postero-
lateral thoracotomy in the fifth or sixth intercostal space.
Dissection of the esophagus in the thorax involved en
bloc removal of the esophagus, with covering pleura,
and all tissue surrounding the esophagus according to
Akiyama [20]. The aorta, tracheal membrane and the
pericardia served as margin for the dissection and the
contralateral pleura was resected as left lateral margin
caudal to the pulmonary veins. The azygos vein was
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served as the dissection was carried out medial to the
ascending vein. The thoracic duct was routinely dis-
sected, ligated, and divided at the level of the diaphragm.
Lymph nodes in the aorta-pulmonary window were dis-
sected. The bronchial branches of the vagal nerve were
preserved. The esophagus was divided orally to the
crossing azygos vein and the oral part of the esophagus
was dissected into the neck. The patient was later
rotated into a supine position for the abdominal and
neck dissections.
Both the transhiatal and the transthoracic approach
involved extensive lymph node dissection in the upper
abdomen and in the lower mediastinum. Tissue and
lymph nodes along the common hepatic artery, the ce-
liac trunk and along the top of the pancreas and splen-
etic artery to the spleen were removed en bloc with
lymph nodes along the lesser curve of the stomach, the
cardia and the specimen. Lymph nodes were not dis-
sected in the neck.
The left gastric artery was divided at the celiac trunk.
The right epiploic arcade and the right gastric artery
were carefully preserved. The spleen was removed in
patients operated during the 1980s but preserved during
the last decade unless its removal was dictated by
bleeding.
The esophagus was substituted by a stomach tube in
83 cases. The tube was approximately 5 cm in diameter
and created prior to lymph node dissection, by firing a
linear stapler several times along the greater curve of the
stomach from the angle at the lesser curve to the top of
the fundus. Pyloroplasty was not performed routinely,
but a Kocher’s maneuver was added in order to improve
the reach of the tube. The left colon was used as esopha-
geal substitute in five patients due to former gastric sur-
gery. In all cases the esophageal substitute was pulled up
through the posterior mediastinum. The cervical esopha-
gus was approached from the left side of the neck for the
anastomosis in all but two patients in whom the anasto-
mosis was performed within the thorax. The cervical
anastomosis was constructed with a two-layer Vicryl 3-0,
(Ethicon, Norderstedt, Germany) interrupted stitches, a
running PDS 4-0 (Ethicon, Norderstedt, Germany) single-
layer technique or a circular stapling instrument according
to the individual operator’s preferences.
Postoperative follow up
The patients were observed in a recovery unit until ven-
tilation was adequate and thereafter in a regular ward.
The pleural tubes were removed when fluid leakage was
less than 100 ml per day. Enteral nutrition was supplied
by a transabdominal jejunal catheter from day one and
the patients were allowed oral feeding according to their
own preferences. Water-soluble oral contrast study(Omnipaque) or endoscopy was performed on suspicion
of dehiscence of the anastomosis.
The specimens entered a routine formaldehyde fixation,
hematoxylin staining and histopathological evaluation at
the department of pathology. No special fat clearance or
staining techniques were employed. The stage of disease
was classified according to the Union for International
Cancer Control’s TNM classification of malignant tumors
in the esophagus (sixth edition) [21].
The patients were followed prospectively at the out-
patient clinic every 6 months for 2 years, and then once a
year for 5 years or until death intervened. Patients referred
from other hospitals were followed at their respective hos-
pitals. A few patients were accepted for palliative chemo-
therapy upon recurrence of disease.
The project was approved by the Regional Committees
for Medical and Health Research Ethics (REK 053228)
and in addition by the Norwegian Directorate of Health
according to the national legislation for biobanks. The
investigation was performed according to the World
Medical Association Declaration of Helsinki and approved
by the Norwegian Social Science Data Services.Statistics
The SPSS statistical package version 17 (SPSS Inc, Chicago,
USA) was used for the descriptive analyses. The independ-
ent sample t-tests assessed differences between groups, and
non-parametric Mann-tests (Whitney U-test) were used
when outliers affected the analyses significantly. Chi-square
tests were used to compare categorical data or Fisher exact
test when the expected number in any cell of the contin-
gency tables was less than five.
Observed patient survival rates were obtained by the
Kaplan–Meier method and presented at 5 (SO5) and 10
(SO10) years with 95% confidence limits. Median time of
survival was calculated and presented with 95% confi-
dence interval (CI). The observed survival curves were
compared with expected survival curves calculated from
mortality rates, available in 1-year intervals (age and
calendar year) for both genders and all birth cohorts,
obtained from Statistics Norway [22]. The expected
curves reflect thus the survival curves of the Norwegian
population with the corresponding composition of gen-
der, age, and year of birth to that of the study group
(Expected number of deaths, Exp) as the patients [23].
The standardized mortality ratio (SMR) was used to
compare the observed to the expected mortality. The
SMR is the ratio of the observed patient mortality and the
mortality in the Norwegian population with the same
composition of gender, age, and year of birth as that of the
study group [24].
In order to compare the SMR of the different covari-
ates (gender, age, stage of disease, surgical approach) a
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fitted [25].
This model includes population mortality rates and ad-
justment for potential confounders (such as gender, age,
stage of disease, surgical approach). The quantities esti-
mated in this model are referred to as relative mortality
ratios (RMR). The RMRs (including the 95% CIs) compares
the SMRs for the different levels of the variables. In an un-
adjusted model, the RMR will be almost identical to the
SMR of one of the covariates divided by the SMR of the
reference category (e.g. RMRGender = SMRFemale/SMRMale).
The analyses were performed with custom and pre-
made Fortran programs [23,25]. Results are pre-
sented as means or median, and with 95% CIs or
range according to appropriate parametric or non-
parametric analyses. A P value of less than 0.05 was
considered statistically significant.Results
The median age of the 88 patients with a R0 resection was
67 (range: 35–88) years and the median age of patients
with transthoracic (n= 33) or transhiatal (n= 55) resection
was 61 (range: 35–77) and 70 (42–88) years, respectively
(P <0.001). Men and women were represented in both
treatment groups, but males (75) outnumbered females
(13) in this series of patients. Clinically important comor-
bidity was present among 36% of the patients. Table 1
summarizes the characteristics of the patients in the two
treatment groups.
Of the patients with a transthoracic procedure 64%
experienced complications and 51% of patients with
a transhiatal procedure experienced complications
(P= 0.152), and some patients experienced several compli-
cations (Table 2). Adverse events during the surgical pro-
cedure occurred among 13% of the patients. Postoperative
complications were dominated by infectious diseasesTable 1 Characteristics of patients subjected to
esophagectomy (R0–resections) for adenocarcinoma of
the esophagus
All Transthoracic Transhiatal P
n= 88 n= 33 n= 55
Gender
females:males 13:75 7:26 6:49 0.222
Age (years) 67 (35–88) 61 (35–77) 70 (42–88) 0.001
Observation (months) 16 (0–203) 20 (3–203) 16 (0–157) 0.179
Comorbidity
Cardiac 18 (20) 4 (12) 14 (25) 0.177
Pulmonary 12 (14) 2 (6) 10 (18) 0.195
Diabetes mellitus 7 (8) 2 (6) 5 (9) 0.698
Total 32 (36) 9 (27) 23 (42) 0.252
Median and range. Statistics by Fishers Exact Test and Mann-Whitney U-test.(43%), of which pneumonia (34%) was most frequent; 14%
of the patients were predisposed to respiratory failure and
ventilator assistance. Clinically important leakage of the
anastomosis or esophageal substitute occurred in 6% of
the patients but was healed by drainage alone in all
patients. Cardiovascular events, thrombosis and embolic
complications were also observed. Five patients died in
hospital following the transhiatal procedure (9.1%). Two
of the five patients were older than 80 years and four of
the patients had symptomatic comorbidity. No surgery-
related deaths occurred following the transthoracic pro-
cedure resulting in an overall in-hospital mortality rate of
5.7%. The median stay in the intensive care unit beyond
the recovery period was 1 day and the hospital stay
of patients with a transthoracic or transhiatal proced-
ure was 17 days (range 10–114) and 15 days (range
3–256), respectively.
The average number of retrieved lymph nodes from the
specimens was 15.6 (95% CI: 13.5–17.6) and varied be-
tween 1 and 49. After transthoracic or transhiatal esopha-
gectomy, the mean number of examined lymph nodes was
17.8 (95% CI: 14.6–21.1) and 14.2 (11.5–16.9), respectively
(P= 0.089). Patients with lymph node metastases had 1
through 19 involved lymph nodes, and the mean number
of involved lymph nodes was 5.9 (95% CI: 3.5–8.2) after
transthoracic and 4.1 (2.9–5.3) after transhiatal esopha-
gectomy (P =0.184).
The depths of tumor invasion and the frequency of
lymph node metastases were similar in the two treat-
ment groups. Approximately 60% of the patients pre-
sented with a pT3 tumor or lymph node metastases
(Table 3). Lymph node metastases were identified in
patients with pT1 tumors (15%) although the frequency
was significantly less than among patients with a pT2
(59%) or pT3 tumor (74%) (P <0.02) (Table 4).
The survival rates after transthoracic or transhiatal
esophagectomy were respectively 31.2% and 27.8% by 5
years, and 21.3% and 16.6% by 10 years, and the median
time of survival after transthoracic or transhiatal esopha-
gectomy was 20.5 months (95% CI: 10.4–57.6) and 16.4
months (95% CI: 10.6–28.7), respectively. The treatment
groups’ similar mortality ratio, indicate that there is no
survival benefit from transthoracic esophagectomy when
compared with survival rates of transhiatal esophagect-
omy (RMR= 1.14, P= 0.63). Figure 1 and Table 5 illus-
trate and summarize the statistics in detail.
The analyses of treatment specific survival rates
allowed for pooling of patients in order to study disease
and impact of patient specific factors on survival. The
overall survival rates of patients after esophagectomy
were 25% and 20.8% by 5 and 10 years, respectively with
a SMR of 6.3 when compared to the general population
(Figure 2a) and the overall median time of survival was
16.4 (95% CI: 12.5–28.7) months.
Table 2 Surgical events and complications of surgery for adenocarcinoma of the esophagus
All resections Transthoracic Transhiatal
n= 88 (%) n= 33 (%) n= 55 (%) P
Surgical events 11 (13) 6 (18) 5 (9) 0.318
- Recurrent nerve injury 5 (6) 3 (9) 2 (4)
- Chylous leakage 4 (5) 2 (6) 2 (4)
- Tracheal injury 2 (2) 1 (3) 1 (2)
Splenectomy 16 (18) 4 (12) 12 (22) 0.197
Postoperative events
Pulmonary failure 12 (14) 6 (18) 6 (11) 0.354
Cardiovascular events 5 (6) 0 5 (9) 0.152
Thromboembolism 6 (7) 4 (12) 2 (3) 0.192
Anastomose leakage 5 (6) 2 (6) 3 (6) 0.905
Infectious complications 38 (43) 18 (55) 20 (36) 0.121
- Pneumonia 30(34) 13 (39) 17 (32)
- Incision 4(5) 3 (9) 1 (2)
- Abdominal abscess 3(3) 1 (3) 2 (4)
- Lung abscess 1(1) 1 (3) 0
Other / minor complications 12 (14) 6 (18) 6 (11) 0.354
Patients with complications 49 (56) 21 (64) 28 (51) 0.275
Intensive care, days (range) 1 (0–69) 1 (0–69) 1 (0–65) 0.457 a
Hospital stay, days (range) 16 (3–256) 17 (10–114) 15 (3–256) 0.086 a
Mortality (in-hospital) 5 (5.7) 0 5 (9.1) 0.152
a Mann–Whitney U test otherwise statistics with Fisher’s exact test.
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vival rates by 5 and 10 years were 52.6% and 48.9%
(Figure 2c), whereas the survival rate was reduced to
7.5% and 3.8% when lymph nodes metastases were
identified (Figure 2e) (RMR 2.22, P = 0.007, Table 5).
Different levels of lymph node involvement were sta-
tistically not associated with differences in survival
rates of transthoracic or transhiatal esophagectomy in
this series of patients. The median times of survival
for patients with or without lymph node metastases
were 10.7 months (95% CI: 7.9–14.9) and 74.0 months
(95% CI: 17.5–166.4), respectively.Table 3 Tumor and lymph node stages among patients
with a transthoracic or transhiatal esophagectomy for
adenocarcinoma of the esophagus
Transthoracic Transhiatal
Total (%) n= 33 (%) n= 55 (%) P
pT 1 13 (15) 3 (9) 10 (18)
pT 2 22 (25) 12 (36) 10 (18) 0.125
pT 3 53 (60) 18 (55) 35 (64)
pN0 34 (39) 13 (39) 21 (38) 1.0
pN1 54 (61) 20 (61) 34 (62)
Stages based on microscopy of the specimens. Statistics by Fisher’s exact test.The effect of tumor invasion on survival is presented
in Figure 2b,d,f. Patients with a pT1 tumor were few and
their survival rate was not statistically different to that of
the general population (SMR= 1.7, 95% CI: 0.7–4.1) and
a median survival time was never reached for this stage of
tumor invasion during a maximal follow up of 196 months.
Median time of survival for patients with a pT2 tumor was
30.4 (95% CI: 9.0–142) months. The median survival time
of patients with a pT3 tumor was 14 (9.2–16.4) months,
and the relative mortality of patients with a pT3–stage was
statistically increased, when compared with patients with
pT1-stage (P=0.024).
Age was a prognostic factor by the time of operation
expressed by a relative mortality of 0.43 per 10 years,Table 4 The frequency of lymph node metastases
according to the tumors depth of invasion into the
esophagus wall
All resections
T-stage no pN 0 (%) pN 1 (%) P
pT 1 13 11 (85) 2 (15) * P <0.02
pT 2 22 9 (41) 13 (59)
pT 3 53 14 (26) 39 (74)
* P <0.02, pT1 different from pT2 and pT3 by Fisher’s exact test.
Figure 1 The observed mortality rate with 95% confidence interval of patients with adenocarcinoma of the esophagus after (a)
transthoracic- or (b) transhiatal esophagectomy. The corresponding mortality rate of the general population with the same composition of
age, gender, and year of birth as the treatment group is presented as the uppermost single plot in each panel.
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patients (with respect to the population) of 57% per 10
years of increasing age. The standardized mortality rate
was especially pronounced for patients with an age
below 70 years (SMR= 2.4) and 60 years (SMR= 7.6)
(Table 5). Patients over the age of 80 years did not reach
a 5-year survival and their median survival time was 6
months (95% CI: 3.3–8.8).Table 5 Survival rates according to operative procedure, lymp
patients treated for adenocarcinoma of the esophagus
N Observed deaths SO(5) 95% CI SO(10
Total 88 72 25.0 16.2–34.4 20.
Transthoracic 33 26 31.2 15.5–46.8 27.
Transhiatal 55 46 21.3 11.5–32.7 16.
pN0 34 20 52.6 34.0–67.5 48.
pN1 54 52 7.5 2.2–15.9 3.
pT1 13 5 68.4 35.6–86.2 57.
pT2 22 18 38.1 18.0–57.0 33.
pT3 53 49 9.4 2.9–18.5 7.
Male 75 62 24.1 15.0–34.2 19.
Female 13 10 30.8 6.8–53.7 30.
<60 28 23 25.0 9.9–41.0 20.
60–69 23 17 27.3 10.8–45.4 27.
70–79 28 23 32.1 15.1–48.7 21.
80+ 9 9 0 –
Age/10 years
SO(5) and SO(10) are the observed survivals in percent (Kaplan–Meier) at 5 and 10 y
by the mortality in the general population with the same composition of age, gend
group. The RMRs compare the SMRs for different levels of the variables RMRGender =The patients’ gender was not a prognostic factor for
relative mortality in this study.
Discussion
This study shows that survival of more than ten years
can be expected after esophagectomy for adenocarcin-
oma of the esophagus without adjuvant or neoadjuvant
radiochemotherapy. Increasing depth of tumor invasionh node metastases and primary tumor infiltration in
) 95% CI SMR 95% CI RMR 95% CI P value
8 11.8–29.9 6.3 5.0–8.0
8 10.4–43.2 6.2 4.2–9.1 1 ref ref
6 7.2–27.6 6.4 4.8–8.5 1.14 0.67–1.96 0.63
9 27.2–64.2 2.8 1.8–4.3 1 ref ref
8 0.5–10.0 12.3 9.4–16.2 2.22 1.24–3.98 0.007
0 14.9–78.9 1.7 0.7–4.1 1 ref ref
3 11.8–52.2 3.8 2.4–6.0 1.47 0.49–4.48 0.50
1 1.9–15.5 13.4 10.1–17.7 3.22 1.16–8.91 0.024
2 10.1–28.9 6.7 5.2–8.6 1 ref ref
8 3.9–53.7 4.7 2.5–8.7 1.84 0.88–3.86 0.11
8 6.7–36.5 7.9 5.3–11.9
3 6.2–45.4 2.4 1.5–3.9
4 7.3–38.3 1.5 0.98–2.2
0 – 1.3 0.7–2.4
0.43 0.35–0.52 <0.001
ears respectively with 95% CI. The SMR is the observed mortality (Obs) divided
er, and year of birth (Expected number of deaths, Exp) as that of the study
SMRFemale/SMRMale , but adjusted for the other factors in the table.
Figure 2 The observed mortality rate with 95% confidence interval of patients with adenocarcinoma of the esophagus. The panels
illustrate the mortality rate of all patients after esophagectomy (a), patients without lymph node involvement (c), patients with lymph node
metastases (e), patients with pT1 tumors (b), patients with pT2 tumors (d), and patients with pT3 tumors (f). The corresponding mortality rate of
the general population with the same composition of age, gender, and year of birth as the treatment group is presented in each panel.
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expectancy significantly, whereas the surgical approach
is less likely to affect the survival rate.
Method
The statistical methods used in this article adjust for
mortality rates from the general population. The ana-
lyses hence mimic a study with a (random) control
group from the population. By doing this we adjust for
the fact that mortality increases with age in the popula-
tion (and also for the patients) and is higher for males
than females. Thus the variables adjusted for in the ana-
lyses are also adjusted for the mortality found in the
general population [23]. Although the patients are repre-
sented in the mortality from the general population, the
age-adjusted incidence rates of esophagus carcinoma inNorway is low (2.8–3.4/100,000) [22], and the amount of
contribution to the mortality found in the general popu-
lation is therefore low.
Morbidity/mortality
Complications are generally observed in 33–71% of
patients after esophagectomy [4,9,26], and it is debated
whether complication rates are related to type of surgical
procedure. Complication rates were statistically not
related to surgical procedure in this study. Similar overall
morbidity rates of transthoracic (53.5%) and transhiatal
(49.3%) esophagectomies are reported by Connors et al.
[27] after analyzing 17,395 esophagectomies. This is sup-
ported by Rentz et al. [28] in an analysis of 562 transthor-
acic and 383 transhiatal resections with a morbidity rate
of 47% and 49%, respectively. Only a randomized
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reveal more chylous leakage, prolonged ventilator support,
longer intensive care and hospital stay after transthoracic
esophageal resection [9].
The overall mortality rate of 5.7% in this series of
patients is similar to that of other reports (2.4–6%)
[4,9,26] and higher mortality rates of 8.4–10% or 8.9–9.9%
are seen after transthoracic or transhiatal esophagectomy
[27,28]. The in-hospital deaths (Table 2) were closely asso-
ciated with advanced age and comorbidity which is more
frequent among patients subject to transhiatal esophagect-
omy in this series of patients (Table 1).
Overall survival
The overall SMR of 6.3 relative to the death rate of
the general Norwegian population emphasizes the ser-
ious prognosis and the vast potential for treatment
improvement among patients with adenocarcinoma of
the esophagus.
Extensive transthoracic en bloc esophagectomy with a
five-year survival rate of 52% [4] is generally considered
more efficient and superior to transhiatal esophagectomy
with survival rate of 31% [5]. Comparative studies sup-
port transthoracic en block resection as a superior pro-
cedure to transhiatal resections for all stages of the
disease including advanced tumors with limited lymph
node metastases [6,7]. Our study shows that any appar-
ent survival benefit of transthoracic over transhiatal sur-
gery is eroded when results are adjusted for year of
birth, age, gender, and stage of disease (Table 5). This is
in concordance with the Dutch trial that adheres to the
Siewert’s classification and includes both type I and type
II cardiac cancers [9,10,16]. The Dutch trial show a su-
periority of transthoracic en bloc resection for type I
adenocarcinoma, whereas transthoracic and transhiatal
esophagectomy obtain similar survival rates for type II
carcinomas [10]. However, the distinction between
tumors close to the GE junction is often blurry and
lymph node dissection during transhiatal esophagectomy
is very different from that of transthoracic esophagect-
omy in the Dutch study, whereas in our series of
patients the lymph node dissection in the abdomen and
at the cardia is identical in the two treatment groups.
Moreover, it may be too ambitious to expect any bene-
ficial effect of extended loco regional treatment on pa-
tient survival rate when the recurrence rate outside the
treatment area is very high. Recurrences after esopha-
gectomy for adenocarcinoma of the esophagus are fre-
quent and approximately 39–56% of recurrences are
related to hematogenous dissemination of tumor cells
[29-31] of which 37.5% of recurrences occur in the liver,
25% in bones, 17.5% in lung and 11% in the brain
[29,32]. The high rates of recurrences outside the dissec-
tion area may very well override and extinguish anypossible beneficial effects of lymph node dissection by
transthoracic or transhiatal esophagectomy on patient
survival.
Survival by stage
The main predictors of outcome in this study, depths of
tumor invasion (pT-stage) and lymph node status (pN-
stage) (Figure 2, Table 5), are known predictors of local
recurrences and distant metastases within one or two
years of the operation [4,10,29,30]. Location of lymph
node metastases is not predictive of recurrence or sur-
vival and therefore not considered in this study [4]. In-
creasing the number of dissected lymph nodes favorably
influences survival rates [33-35]. The varying number of
examined lymph nodes in this study may affect precision
in staging of patients and distort some of the results in
this study by stage migration [35]. In order to improve
staging lymph nodes are now harvested from the speci-
mens by the operating surgeon.
Transhiatal esophagectomy is often reported with a
more limited lymph node dissection than transthoracic
esophagectomy [9,35]. In this study lymph node dissec-
tion during transthoracic and transhiatal esophagectomy
is identical in the abdomen and at the cardia. Any appar-
ent numeric difference between the two treatment
groups is probably related to the additionally dis-
sected lymph nodes in the upper mediastinum during
transthoracic esophagectomy.
The complexity of lymph node metastases and out-
come by surgical approaches are shown in subanalyses
of the Dutch randomized trial [10]. Survival rates of
extended transthoracic esophagectomy is superior to
that of limited transhiatal esophagectomy when a mod-
erate number of lymph nodes are present (1–8 involved
notes), but the survival rates are similar when lymph
nodes are uninvolved or massively involved (>8 involved
notes) [10]. Similarly Johansson et al. [7] show that
patients undergoing transthoracic en bloc resection for
T3 N1 adenocarcinoma of the distal esophagus had a
survival benefit over those treated with transhiatal resec-
tion when less than 9 involved lymph nodes are present.
Although the lethality among patients with lymph node
metastases is high (Figure 2, Table 5), extended me-
diastinal and abdominal dissection to remove pos-
sibly involved nodes is supported by several authors
[7,31,32,36].
The depth of tumor invasion is strongly associated
with the risk of lymph node metastases (Table 4). Only
15% of patients with a pT1 tumor are at risk of having
lymph node metastases. Intramucosal carcinomas are
rarely associated with lymph node metastases (8% when
confined in lamina propria) (20% when invading the mu-
cosal muscular layer), and limited or even vagal sparing
resections are justified in these patients [37]. Locally
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tastases (Table 4) and require more extended surgical
options.
It is important to realize that the number of patients
eligible for curative resections is limited (60%) and the
frequency of regional metastases is high (Tables 3, 4). A
tailored treatment strategy therefore requires an ambi-
tious preoperative work up to identify patients with pos-
sible metastases. Preoperative loco regional staging of
esophageal cancer with EUS provides excellent T staging
accuracy and the accuracy for N staging compares well
with positron emission tomography and CT [38], EUS is
also associated with improved survival stratification in
patients with esophageal adenocarcinoma [39]. Although
the total number of involved lymph nodes is not readily
available for preoperative stratification of surgical treat-
ment, the coherence between T stage and N stage seen
in this study (Table 4) supports a strategy based on a
thorough preoperative evaluation of T stage. We there-
fore favor T stage and N stage rather than aggregated
stages in order to establish a clinical fundament for deci-
sion making and comparison in clinical practice.
Patients with adenocarcinoma in the esophagus at an
age of less than 60 years have the highest SMRs due to the
longer life expectancy of their corresponding matched
controls in the background population (Table 5). These
patients are therefore likely to benefit the most from
multimodal neoadjuvant or adjuvant therapy. The shorter
life expectancy of the aged background population
explains less SMRs of aged patients. Patients of 80 years
or more in this study are prone to in-hospital mortality
and a limited length of survival following esophagectomy.
This group of patients may therefore benefit from a more
palliative approach and esophagectomy may be limited to
a selected group of well-functioning patients of 80 years
or more.Material
The exclusion of patients with residual tumor (R1 or
2) violates the intention to treat principle, but reduces
the number of confounding factors in the comparison
of transthoracic and transhiatal esophagectomy. More-
over, high-resolution CT, 8F-Fluorodeoxyglucose-positron
emission tomography (FDG-PET) and EUS during pre-
operative work up are now also likely to identify most of
these patients prior to surgery [18,40,41]. The allocation
of patients to transthoracic or transhiatal esophagectomy
is not random and patients with a transhiatal esophagect-
omy are somewhat older than patients with transthoracic
esophagectomy. However, stages of disease (Table 3) are
similarly represented in the two treatment groups and the
demographic selection biases are adjusted for by statistical
methods. Results are therefore considered valid.Implications
This study supports both transthoracic and transhiatal
esophagectomy as valid options with similar survival and
morbidity rates among patients operated without neoad-
juvant radiochemotherapy. However, the transthoracic
approach is associated with superior survival rates for
type I adenocarcinoma in larger series and should prob-
ably be the method of choice for patients that can sus-
tain the risk of more morbidity and a longer hospital
stay [9,10].
The distinctions in Siewert’s classification are not
recognized in later classifications [16,17]. We therefore
advocate transthoracic esophagectomy to patients with
adenocarcinoma at the distal esophagus that cannot be
visualized at the cardia with a looped endoscope.
The work up of these patients is complex and despite
an increasing incidence of adenocarcinoma at the distal
esophagus and cardia, care for these patients should be
confined to a limited number of centers [42].
Conclusion
Esophagectomy for adenocarcinoma of the esophagus
may convey long-term survival of more than ten years
without addition of adjuvant therapy. The prognoses are
however closely associated with stage of disease and less
influenced by surgical approach. The SMR of 6.3 empha-
sizes a vast potential for improvement of treatment, and
strategies for the future should probably involve new
multimodal therapy and detection of disease at an early
stage.
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